<DOC>
	<DOCNO>NCT00005026</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient stage III stage IV ovarian epithelial primary peritoneal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage III Stage IV Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility administer multiple course carboplatin topotecan without excessive dose modification course delay patient previously untreated ovarian epithelial primary peritoneal carcinoma . II . Describe response rate progression-free interval patient treatment regimen . III . Determine pharmacokinetic pharmacodynamic parameter related sequence carboplatin topotecan administration patient . OUTLINE : Patients assign one three treatment regimen . Regimen I : Patients receive carboplatin IV 30 minute day 1 follow topotecan IV 30 minute day 1-3 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Regimen II : Patients receive topotecan IV 30 minute day 1-3 follow carboplatin IV 30 minute day 3 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Regimen III : Patients receive topotecan IV 30 minute day 1-5 follow carboplatin IV 30 minute day 5 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment continue every 21 day 4 course absence disease progression unacceptable toxicity . Patients follow 1 month every 3 month 1 year . PROJECTED ACCRUAL : A total 15-80 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ovarian epithelial primary peritoneal carcinoma Prior surgery require within past 12 week Either optimal ( great 1 cm residual disease ) suboptimal residual disease follow initial surgery No ovarian epithelial tumor low malignant potential ( borderline tumor ) The follow histologic epithelial cell type eligible : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell carcinoma Adenocarcinoma otherwise specify Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner tumor PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least low limit normal Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT alkaline phosphatase great 2.5 time ULN No acute hepatitis Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina No myocardial infarction within past 6 month Abnormal cardiac conduction ( e.g. , bundle branch block , heart block ) allow stable past 6 month Other : No septicemia severe infection No severe gastrointestinal bleeding No concurrent prior invasive malignancy within past 5 year except nonmelanoma skin cancer No great grade 1 neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Other : No prior cancer treatment contraindicates study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>